Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients

References

• Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015;27:1.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–11. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, Sasako M, Van De Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449. doi:10.1016/S1470-2045(10)70070-X.
   PubMed Web of Science ®Google Scholar
• Nishida T. Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet. 2012;379(9813):291–292. doi:10.1016/S0140-6736(11)61928-4.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi:10.1038/nrc1074.
   PubMed Web of Science ®Google Scholar
• Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34(12):1350–1357. doi:10.1200/JCO.2015.63.7215.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–584.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 2018;36(28):2836–2844. doi:10.1200/JCO.2017.76.6212.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal S, Shah M, Metges JP, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668. doi:10.1038/nrclinonc.2017.88.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207–211. doi:10.1126/science.aad0095.
   PubMed Web of Science ®Google Scholar
• Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2020;20(2):128–136. doi:10.1038/s41577-019-0223-7.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol. 2014;14(11):768–774. doi:10.1038/nri3740.
   PubMed Web of Science ®Google Scholar
• Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood. 2004;104(7):1952–1960. doi:10.1182/blood-2004-03-1206.
   PubMed Web of Science ®Google Scholar
• Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV, et al. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat. 2016;155(3):615–616. doi:10.1007/s10549-016-3713-3.
   PubMed Web of Science ®Google Scholar
• Sambandam Y, Sundaram K, Liu A, Kirkwood KL, Ries WL, Reddy SV. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene. 2013;32(1):97–105. doi:10.1038/onc.2012.24.
   PubMed Web of Science ®Google Scholar
• Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human nonsmall cell lung carcinoma. Int J Oncol. 2014;45(6):2232–2240. doi:10.3892/ijo.2014.2688.
   PubMed Web of Science ®Google Scholar
• Wei Y, Lin C, Li H, Xu Z, Wang J, Li R, Liu H, Zhang H, He H, Xu J, et al. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Cancer Immunol Immunother. 2018;67(2):261–269. doi:10.1007/s00262-017-2083-y.
   PubMed Web of Science ®Google Scholar
• Duan Z, Gao J, Zhang L, Liang H, Huang X, Xu Q, Zhang Y, Shen T, Lu F. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget. 2015;6(42):44239–44253. doi:10.18632/oncotarget.6235.
   PubMedGoogle Scholar
• Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LWK, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW, et al. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009;283(1):29–35. doi:10.1016/j.canlet.2009.03.022.
   PubMed Web of Science ®Google Scholar
• Qi XW, Xia SH, Yin Y, Jin L-F, Pu Y, Hua D, Wu H-R. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. Eur Rev Med Pharmacol Sci. 2014;18:1916–1924.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Ryu KJ, Hong M, Ko YH, Kim WS. The serum CXCL13 level is associated with the glasgow prognostic score in extranodal NK/T-cell lymphoma patients. J Hematol Oncol. 2015;8:49. doi:10.1186/s13045-015-0142-4.
   PubMed Web of Science ®Google Scholar
• Del Grosso F, Coco S, Scaruffi P, Stigliani S, Valdora F, Benelli R, Salvi S, Boccardo S, Truini M, Croce M, et al. Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Mol Cancer Res. 2011;9(7):815–823. doi:10.1158/1541-7786.MCR-10-0367.
   PubMed Web of Science ®Google Scholar
• Katakai T, Suto H, Sugai M, Gonda H, Togawa A, Suematsu S, Ebisuno Y, Katagiri K, Kinashi T, Shimizu A, et al. Organizer-like reticular stromal cell layer common to adult secondary lymphoid organs. J Immunol. 2008;181(9):6189–6200. doi:10.4049/jimmunol.181.9.6189.
   PubMed Web of Science ®Google Scholar
• Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol. 2008;20(1):14–25. doi:10.1016/j.smim.2007.12.001.
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Migliori E, Buisseret L, De Wind A, Brohée S, Garaud S, Noël G, C.v. LD, Lodewyckx J-N, Naveaux C, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. 2017;2(11):11. doi:10.1172/jci.insight.91487.
   Web of Science ®Google Scholar
• Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350–2360. doi:10.1172/JCI46102.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356. e16. doi:10.1016/j.cell.2017.05.035.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994–1004. doi:10.1038/s41591-018-0057-z.
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–663. doi:10.1146/annurev-immunol-031210-101400.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schumacher TN, Cell T. Dysfunction in Cancer. Cancer Cell. 2018;33(4):547–562. doi:10.1016/j.ccell.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Lauren P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64:31–49. doi:10.1111/apm.1965.64.1.31.
   PubMedGoogle Scholar
• Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449. doi:10.1038/nm.3850.
   PubMed Web of Science ®Google Scholar
• Ammirante M, Shalapour S, Kang Y, Jamieson CAM, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc National Acad Sci. 2014;111(41):14776–14781. doi:10.1073/pnas.1416498111.
   PubMed Web of Science ®Google Scholar
• Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, Lin Z, Xiong Y, Wang J, Chang Y, et al. Intratumoral CXCL13+CD8+ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J ImmunoTher Cancer. 2021;9(2):e001823. doi:10.1136/jitc-2020-001823.
   PubMed Web of Science ®Google Scholar
• Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H, Zhang W, Xu J. Association of O6-methylguanine-DNA methyltransferase protein expression with postoperative prognosis and adjuvant chemotherapeutic benefits among patients with stage II or III gastric cancer. JAMA Surg. 2017;152(11):e173120. doi:10.1001/jamasurg.2017.3120.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794–801. doi:10.1136/gutjnl-2015-310839.
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–196. doi:10.1126/science.aad0501.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang X, Guo H, Fu L, Pan G, Sun Y. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. Mol Cell Biochem. 2015;400(1–2):287–295. doi:10.1007/s11010-014-2285-y.
   PubMed Web of Science ®Google Scholar
• Li C, Kang D, Sun X, Liu Y, Wang J, Gao P. The effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling. Biomed Res Int. 2015;2015:345413.
   PubMed Web of Science ®Google Scholar
• Yu C, Zhang Y. Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine. 2019;123:154785. doi:10.1016/j.cyto.2019.154785.
   PubMed Web of Science ®Google Scholar
• Zhong C, Song Z, Li M. Gastric cancer patients display a distinctive population of IFNg+IL10+ double positive CD8 T cells, which persists longer during prolonged activation. Exp Cell Res. 2019;382(2):111487. doi:10.1016/j.yexcr.2019.06.032.
   PubMed Web of Science ®Google Scholar
• Meng X, Yu X, Dong Q, Xu X, Li J, Xu Q, Ma J, Zhou C. Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer. Oncol Lett. 2018;16(3):3917–3922. doi:10.3892/ol.2018.9112.
   PubMed Web of Science ®Google Scholar
• Ding Y, Shen J, Zhang G, Chen X, Wu J, Chen W. CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer. Oncotarget. 2015;6(36):38901–38911. doi:10.18632/oncotarget.5644.
   PubMedGoogle Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4–328rv4. doi:10.1126/scitranslmed.aad7118.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344–1355. doi:10.1158/2326-6066.CIR-15-0097.
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc National Acad Sci. 2008;105(39):15016–15021. doi:10.1073/pnas.0801497105.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665–674. doi:10.1038/s41577-019-0221-9.
   PubMed Web of Science ®Google Scholar